Changgui Li | Gout | Innovative Research Award

Posted on by Global HRM Awards

Innovative Research Award

Changgui Li
Affiliation Xiamen University
Country China
Scopus ID 35313424500
Documents 100+
Citations 29
h-index 3
Subject Area  Gout
Event Global HRM Awards

Changgui Li
Xiamen University,  China

Changgui Li is a researcher recognized for scholarly contributions in rheumatology, gout research, hyperuricemia, metabolomics, inflammatory disease mechanisms, renal complications, and translational medicine. His publication record demonstrates active participation in collaborative scientific investigations related to gout pathogenesis, metabolic disorders, therapeutic interventions, biomarker discovery, and genomic analyses.[1]

His research activities include studies involving metabolomics, genome-wide association analyses, inflammatory biomarkers, clinical cohort investigations, and therapeutic evaluations associated with gout and metabolic diseases.[2]

Abstract

Changgui Li has contributed to the advancement of rheumatology and metabolic disease research through investigations involving gout pathophysiology, hyperuricemia, metabolomics, inflammatory biomarkers, renal complications, microbiota regulation, and therapeutic response evaluation. His studies integrate clinical investigations, genomic analyses, metabolomic profiling, machine learning approaches, and translational medicine methodologies for improved understanding of gout-related disorders.[3]

Keywords

Rheumatology; Gout; Hyperuricemia; Metabolomics; Biomarkers; Genome-Wide Association Studies; Inflammatory Diseases; Renal Function; Precision Medicine; Clinical Research.

Introduction

Gout and hyperuricemia represent significant public health concerns associated with inflammatory responses, renal dysfunction, metabolic abnormalities, and chronic disease progression. Contemporary rheumatology research increasingly focuses on biomarker discovery, metabolic profiling, precision medicine, and therapeutic optimization for improved patient outcomes.[4]

Research Profile

The research profile of Changgui Li includes scholarly publications in rheumatology, inflammatory diseases, metabolomics, endocrinology, nephrology, and clinical medicine journals. His work has appeared in Arthritis and Rheumatology, Arthritis Research and Therapy, Rheumatology, Frontiers in Endocrinology, Annals of Medicine, Chemosphere, and other indexed scientific journals.[6]

Research Contributions

Changgui Li has contributed to studies investigating metabolic biomarkers associated with gout flares, obesity-related disease mechanisms, renal urate underexcretion, inflammatory responses, and microbiota-mediated metabolic regulation.[5]

His collaborative investigations additionally include genome-wide association analyses involving large international cohorts, machine learning-assisted predictive models, therapeutic comparative effectiveness studies, and epidemiological analyses examining disease prevalence and clinical outcomes.

Publications

  • Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares, Arthritis and Rheumatology, 2023.
  • Novel genetic loci in adolescent-onset gout derived from whole genome sequencing of a Chinese cohort, medRxiv, 2023.
  • Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout, Rheumatology, 2023.
  • A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout, Arthritis Research and Therapy, 2022.
  • Kidney and plasma metabolomics provide insights into the molecular mechanisms of urate nephropathy in a mouse model of hyperuricemia, Biochimica et Biophysica Acta – Molecular Basis of Disease, 2022.
  • Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion, Arthritis and Rheumatology, 2022.

Research Impact

The research contributions of Changgui Li support advancements in rheumatology, metabolic disease management, inflammatory biomarker discovery, metabolomic profiling, microbiota regulation, and precision medicine approaches. His studies contribute to improved understanding of gout progression, renal complications, metabolic dysfunction, and therapeutic response mechanisms

Award Suitability

Changgui Li demonstrates a sustained research profile in rheumatology and metabolic medicine through publication activity, international collaboration, translational investigations, and interdisciplinary scientific contributions. His work aligns with research excellence recognition criteria emphasizing scientific quality, innovation, clinical relevance, and evidence-based medical advancement.

Conclusion

The scholarly activities of Changgui Li contribute to the advancement of gout research, metabolomics, inflammatory disease understanding, and translational rheumatology science. His research demonstrates ongoing engagement in multidisciplinary investigations focused on improving clinical understanding and therapeutic approaches for metabolic and inflammatory disorders.

References

  1. ORCID. (2026). Changgui Li ORCID profile and scholarly activities.
    https://orcid.org/0000-0002-4622-3731
  2. Elsevier Scopus. (2026). Indexed research publications and collaborative studies associated with Changgui Li.
    https://www.scopus.com/authid/detail.uri?authorId=57252600000
  3. Arthritis and Rheumatology. (2023). Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares.
    https://doi.org/10.1002/art.42635
  4. Annals of Medicine. (2022). Prevalence and related factors of hyperuricaemia in Chinese children and adolescents: a pooled analysis of 11 population-based studies.
    https://doi.org/10.1080/07853890.2022.2083670
  5. Acta Pharmaceutica Sinica B. (2023). Pathophysiology of obesity and its associated diseases.
    https://doi.org/10.1016/j.apsb.2023.01.012
  6. Rheumatology (United Kingdom). (2023). Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout.
    https://doi.org/10.1093/rheumatology/keac507